{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:48:25Z","timestamp":1791658105547,"version":"4.3.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejso.2026.112201","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:03:30Z","timestamp":1791356610000},"page":"112201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant abemaciclib does not increase delayed reconstructive morbidity after tissue-expander breast reconstruction: A multi-institutional propensity-matched analysis"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5546-3561","authenticated-orcid":false,"given":"Yash","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela J.","family":"Godin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana H.","family":"Mahdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir B.","family":"Behnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5955-1734","authenticated-orcid":false,"given":"Saif","family":"Badran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejso.2026.112201_bib1","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.ejso.2026.112201_bib3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.30699\/jogcr.7.3.221","article-title":"Survival pattern depending on hormone receptor status, stages of breast cancer and social-economic status- a cohort study","volume":"7","author":"Baisil","year":"2022","journal-title":"J Obstetr Gynecol Cancer Res"},{"key":"10.1016\/j.ejso.2026.112201_bib4","first-page":"153","article-title":"The effect of estrogen receptor status on survival in breast cancer patients in Ethiopia. Retrospective cohort study","volume":"14","author":"Belete","year":"2022","journal-title":"Breast Cancer"},{"issue":"7","key":"10.1016\/j.ejso.2026.112201_bib5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJMc1112823","article-title":"Adjuvant trastuzumab in HER2-Positive breast cancer","volume":"366","author":"Kaji","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejso.2026.112201_bib6","article-title":"Neoadjuvant\u2013adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial","volume":"15","author":"Huang","year":"2024","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.ejso.2026.112201_bib7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10549-017-4653-2","article-title":"Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I\u2013III HER2-positive breast cancer","volume":"169","author":"Foldi","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ejso.2026.112201_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26019-y","article-title":"Neoadjuvant T-DM1\/pertuzumab and paclitaxel\/trastuzumab\/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial","volume":"12","author":"Clark","year":"2021","journal-title":"Nat Commun"},{"issue":"34","key":"10.1016\/j.ejso.2026.112201_bib10","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2026.112201_bib11","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.annonc.2021.09.015","article-title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study","volume":"32","author":"Harbeck","year":"2021","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejso.2026.112201_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104683","article-title":"How should we manage abemaciclib in the peri-operative period during secondary breast reconstruction: balancing oncologic benefit and surgical safety","volume":"85","author":"Cazenave","year":"2026","journal-title":"Breast"},{"issue":"1\u20132","key":"10.1016\/j.ejso.2026.112201_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17434440.2023.2288911","article-title":"The current use of tissue expanders in breast reconstruction: device design, features, and technical considerations","volume":"21","author":"Cho","year":"2024","journal-title":"Expert Rev Med Dev"},{"issue":"6","key":"10.1016\/j.ejso.2026.112201_bib14","doi-asserted-by":"crossref","first-page":"1065e","DOI":"10.1097\/PRS.0000000000011432","article-title":"Disparity reduction in u. S. Breast reconstruction: an analysis from 2005 to 2017 using 3 nationwide data sets","volume":"154","author":"Rubenstein","year":"2024","journal-title":"Plast Reconstr Surg"},{"issue":"Suppl 1","key":"10.1016\/j.ejso.2026.112201_bib15","article-title":"The incidence of and risk factors for breast infections after tissue expander placement","volume":"5","author":"Chumble","year":"2023","journal-title":"Aesthet Surg J Open Forum"},{"issue":"7","key":"10.1016\/j.ejso.2026.112201_bib16","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.bjps.2022.01.050","article-title":"Infections after mastectomy and tissue expander placement: a multivariate regression analysis","volume":"75","author":"Kraenzlin","year":"2022","journal-title":"J Plast Reconstr Aesthetic Surg"},{"issue":"2","key":"10.1016\/j.ejso.2026.112201_bib17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/PRS.0000000000012325","article-title":"Anticancer agents and their impact on breast reconstruction: a guide for plastic surgeons based on systematic review and expert consensus","volume":"157","author":"Zona","year":"2026","journal-title":"Plast Reconstr Surg"},{"issue":"2","key":"10.1016\/j.ejso.2026.112201_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"10.1016\/j.ejso.2026.112201_bib20","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.annonc.2022.03.006","article-title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study","volume":"33","author":"Rugo","year":"2022","journal-title":"Ann Oncol"},{"issue":"2, Supplement","key":"10.1016\/j.ejso.2026.112201_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2024.07.691","article-title":"Complications of implant-based reconstruction and post-mastectomy radiation in the era of adjuvant CDK4\/6 inhibitors","volume":"120","author":"Iqbal","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejso.2026.112201_bib22","series-title":"71st annual meeting of the plastic surgery research council","article-title":"Implications of Cdk4\/6 inhibitors on outcomes after autologous breast reconstruction","author":"Neira","year":"2026"},{"issue":"3","key":"10.1016\/j.ejso.2026.112201_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/1759-7714.70217","article-title":"Abemacilib-related radiation recall dermatitis post breast reconstruction: a case report and literature review","volume":"17","author":"Jia","year":"2026","journal-title":"Thorac Cancer"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326008206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326008206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:50:46Z","timestamp":1791654646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326008206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0748798326008206"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112201","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant abemaciclib does not increase delayed reconstructive morbidity after tissue-expander breast reconstruction: A multi-institutional propensity-matched analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112201","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"112201"}}